Ose Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for activation and regulation of the immune system in Immuno-Oncology and Immuno-Inflammation.

Ose Immunotherapeutics

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Poxel SA is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders.

Metric
Company Name	Ose Immunotherapeutics	Biotech 365	Neovacs S.A.	Poxel SA
Symbol			ALNEV
MSH ID	COM:OSE-IMMUNO	COM:BIOTECH-365	COM:NEOVACS	COM:POXEL
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Financial Services & Finance	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology Business Services	Biotechnology	Biotechnology
Country	FR	FR	FR	FR
Stage			Post-IPO Debt	Post-IPO Debt
Employee Count			22
Website	ose-immuno.com	biotech-365.com	neovacs.com	poxel.com
LinkedIn			neovacs	poxel
Founders

Metric
Market Cap			52.99K
Enterprise Value
Monthly Web Traffic	747	68		4.88K
Web Traffic Growth	-0.61	-0.57		-0.63
Valuation
Raised Capital			4.77M	50M

Metric
Revenue			563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit			-7.13M
EBITDA			-7.12M
Operating Income			-7.30M
Net Income			-9.24M
EPS			-0.00
Diluted EPS			-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			-9.71
Operating Profit Margin			-12.95
EBITDA Margin			-12.64
Net Profit Margin			-16.39
Return on Equity			-0.12
Return on Assets			-0.11
Return on Capital Employed			-0.14

COM:OSE-IMMUNO

Ose Immunotherapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			5.78
EV Multiple			-0.04

Metric
Days Sales Outstanding
Days Payables Outstanding			1.22K
Days Inventory Outstanding
Operating Cycle			11.67K
Cash Conversion Cycle			11.39K
Asset Turnover			0.01

Metric
Operating Cash Flow			-2.02M
Free Cash Flow			-2.24M
Cash Flow to Debt			-1.47
Operating Cash Flow/Sales			-3.59
Free Cash Flow Yield			-0.00

Metric
Cash & Equivalents			936.97K
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization			0.06
Debt to Assets			0.02
Current Ratio			2.32
Quick Ratio			1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue